Evaluation of nasal mucociliary clearance by saccharine test in rheumatoid arthritis

•Nasal involvement has not been fully addressed in Rheumatoid Arthritis (RA).•Nasal Mucociliary Clearance (NMC) time of RA patients was within normal limits and was similar to the control group.•Anti-cyclic citrated peptide (Anti-CCP) positivity may affect NMC time in RA patients. We aimed to reveal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brazilian journal of otorhinolaryngology 2022-11, Vol.88 (Suppl 5), p.S42-S46
Hauptverfasser: Yücel, Hilal, Eşmen, Serpil Ergülü
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Nasal involvement has not been fully addressed in Rheumatoid Arthritis (RA).•Nasal Mucociliary Clearance (NMC) time of RA patients was within normal limits and was similar to the control group.•Anti-cyclic citrated peptide (Anti-CCP) positivity may affect NMC time in RA patients. We aimed to reveal whether there is nasal involvement by examining the Nasal Mucociliary Clearance (NMC) and the relationship between this activity and disease severity in Rheumatoid Arthritis (RA) patients. In this prospective study, NMC time, disease activity (Disease Activity Score 28) and blood parameters of RA patients (n = 87) were investigated and compared with the healthy control group (n = 50). In addition, the relationship between DAS 28 and NMC was investigated. The mean NMC of the RA group was 9.51 ± 3.54 min, the mean NMC of the control group was 8.69 ± 2.85 min, and there was no significant difference between the two groups. There was no correlation between NMC and disease duration, and DAS 28. The mean NMC of the RA patients with Anti Cyclic Citrulled Peptide (Anti-CCP) positive was significantly higher than the negative ones. Although there was no significant difference in NMC values between the RA and control group, the NMC of the Anti-CCP positive patients was higher. Level 2.
ISSN:1808-8694
1808-8686
1808-8686
DOI:10.1016/j.bjorl.2021.08.005